Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNMA1 | Q12791 | 5/20 | 0.58 |
| ▸ | P2RX1 | P51575 | 8/20 | 0.51 |
| ▸ | TMPRSS4 | Q9NRS4 | 7/20 | 0.50 |
| ▸ | P2RX4 | Q99571 | 4/20 | 0.50 |
| ▸ | P2RX7 | Q99572 | 4/20 | 0.50 |
| ▸ | STAT3 | P40763 | 1/20 | 0.46 |
| ▸ | KDR | P35968 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.44 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13907151 | 0.85 | STAT3 (0.64) | KCNMA1P2RX1TMPRSS4STAT3 | |
| SCHEMBL30472740 | 0.84 | KCNMA1 (0.64) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL10114085 | 0.82 | KCNMA1 (0.61) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL13524051 | 0.82 | KCNMA1 (0.61) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL13907159 | 0.82 | STAT3 (0.61) | STAT3KDR | |
| SCHEMBL13951816 | 0.82 | KCNMA1 (0.48) | KCNMA1STAT3 | |
| SCHEMBL24823416 | 0.79 | KCNMA1 (0.57) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL13055666 | 0.79 | KCNMA1 (0.57) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL24460244 | 0.79 | KCNMA1 (0.57) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 | |
| SCHEMBL17770446 | 0.79 | TMPRSS4 (0.59) | KCNMA1P2RX1TMPRSS4P2RX4P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES, L.C. | 2012-05-17 | — | — | US | disclosed |
| US-8124632-B2 | Alkylsulfonyl-substituted thiazolide compounds | ROMARK LABORATORIES, L.C. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | ROMARK LABORATORIES L.C. | 2009-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122939-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | KCNMA1 3670/4885P2RX1 4408/4885TMPRSS4 72/4885 |
| US-20090036467-A1 | ALKYLSULFONYL-SUBSTITUTED THIAZOLIDE COMPOUNDS | HAVCR2, EIF2AK2, AADAC | KCNMA1 3670/4885P2RX1 4408/4885TMPRSS4 72/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.